Therapeutics News and Research

RSS

Scientists identify new drug target to treat heart arrhythmias

Scientists at The Ohio State University Davis Heart and Lung Research Institute have identified a new target they hope will help make the next drug discovery for patients suffering from heart arrhythmias happen sooner.

9 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

Impax Laboratories receives FDA notice regarding Hayward manufacturing facility

Impax Laboratories, Inc. today announced that it received written notice from the United States Food and Drug Administration verifying that the Company has successfully addressed all items raised by the FDA in the May 2011 Warning Letter relating to its Hayward, California manufacturing facility.

8 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

Study demonstrates effectiveness of new approach to protect humans from infectious disease

There are two common approaches to protecting humans from infectious disease: Targeting pathogens and parasites with medicines like antibiotics, or dealing with the conditions that allow transmission.

8 Sep 2015

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proof-of-concept ("POC") trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer ("NSCLC") in China.

4 Sep 2015

PTC Therapeutics announces recipients of STRIVE Awards

PTC Therapeutics, Inc. is pleased to announce five recipients of its first-ever global awards program, the STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment), designed to aid nonprofit organizations that are committed to serving the Duchenne muscular dystrophy (DMD) community.

4 Sep 2015

14th APS symposium highlights role of endothelin in many biological functions

Endothelin (ET) is a peptide produced by cells in the blood vessels and has powerful vessel-constricting effects. Although endothelin is mainly associated with its role in blood pressure control and cardiovascular diseases, it continues to appear in other physiological functions and diseases.

4 Sep 2015

Endothelin system offers potential therapeutic target for ALS

Amyotrophic lateral sclerosis (ALS) is a disorder in which cells of the nervous system die, leading to muscle weakness that impacts breathing, movement and other physical functions.

4 Sep 2015

Valerion announces positive results from non-clinical pilot study of VAL-1221 for treatment of Pompe disease

Valerion Therapeutics, LLC yesterday announced positive results from a non-clinical "proof of concept" pilot study for a novel humanized antibody and acid alpha glucosidase (GAA) fusion candidate for the treatment of Pompe disease.

3 Sep 2015

Study reveals new epigenetic mechanism underlying progression of cancer tumors

Aggressive cancer growth and alterations in gene activity without changes in DNA sequence (epigenetics) are associated with mutant p53 proteins, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

3 Sep 2015

Scientists pinpoint neurons responsible for alcohol consumption

Scientists have pinpointed a population of neurons in the brain that influences whether one drink leads to two, which could ultimately lead to a cure for alcoholism and other addictions.

3 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Study reveals presence of new genetic mutation in melanoma cancer cells

There is strong evidence that the protein complex APC/C may function as a tumor suppressor in multiple cancers including lymphoma, colorectal and breast cancer, and now melanoma. A new study has revealed that a genetic mutation leading to repression of a specific protein, Cdh1, which interacts with APC/C, is present in melanoma cancer cells.

3 Sep 2015

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

3 Sep 2015

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Sangamo BioSciences, Inc., a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc, have agreed to revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease.

2 Sep 2015

University of Maryland Medicine offers MRI-guided focused ultrasound treatment to Parkinson's patients

University of Maryland Medicine (the University of Maryland Medical Center and the University of Maryland School of Medicine) and its Center for Metabolic Imaging and Image-Guided Therapeutics (CMIT) has begun to use MRI-guided focused ultrasound on a deep structure within the brain related to Parkinson's disease - the globus pallidus.

2 Sep 2015

Researchers reveal how the brain manages multitasking

What makes someone better at switching between different tasks? Looking for the mechanisms behind cognitive flexibility, researchers at the University of Pennsylvania and Germany's Central Institute of Mental Health in Mannheim and Charité University Medicine Berlin have used brain scans to shed new light on this question.

2 Sep 2015

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease.

2 Sep 2015

Therapeutics News and Research

Scientists identify new drug target to treat heart arrhythmias

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Impax Laboratories receives FDA notice regarding Hayward manufacturing facility

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Study demonstrates effectiveness of new approach to protect humans from infectious disease

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

PTC Therapeutics announces recipients of STRIVE Awards

14th APS symposium highlights role of endothelin in many biological functions

Endothelin system offers potential therapeutic target for ALS

Valerion announces positive results from non-clinical pilot study of VAL-1221 for treatment of Pompe disease

Study reveals new epigenetic mechanism underlying progression of cancer tumors

Scientists pinpoint neurons responsible for alcohol consumption

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Study reveals presence of new genetic mutation in melanoma cancer cells

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

University of Maryland Medicine offers MRI-guided focused ultrasound treatment to Parkinson's patients

Researchers reveal how the brain manages multitasking

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Industry Focus eBook - Biotechnology (4th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News